About
We are proud to serve a purpose beyond ourselves.
Better outcomes for patients with unmet needs
The Abacus Medicine Group was founded in 2004 to improve access to critical medicines throughout Europe, driven by the vision of supporting better healthcare and outcomes for patients with unmet medical needs.
Abacus Medicine Pharmaceuticals (AMP) is a commercial-stage pharmaceutical company dedicated to partnering with innovators to launch and commercialize specialty medicines across Europe.
Backed by the Abacus Medicine Group, we combine European infrastructure, financial strength, and hands-on market expertise to deliver highly effective product launches and accelerate patient access to new therapies.
Our partnering focused model ensures that every collaboration receives dedicated attention and execution excellence based on deep organizational expertise. Our agile operating model and technological enablement allow us to treat each product as a true priority.
Through recent partnerships, we have demonstrated success in specialty go-to-market – from acting as regional affiliate in select geographies to European rollouts. As we continue to grow, we aim to be recognized as a trusted European partner for go-to-market and commercialization, helping transform innovation into meaningful patient impact.
Milestones
Sharing a common purpose
Abacus Medicine Pharmaceuticals strives to create universal access to rare diseases medicines through impactful commercialisation solutions.
We aim:
- to empower our partners with bold and innovative commercialisation solutions.
- to strengthen key stakeholder relationships through transparent, engaging, and trusting collaboration.
- to advance patient well-being by ensuring swift and caring access to transformative treatments.
Leadership
Our experienced management team has extensive experience working for and with global pharmaceutical and biotech firms serving the rare disease community.
Jörg Schulze
Jörg joined AMP in 2025 after leading Bristol-Meyers Squibb's Nordic cluster as General Manager, where he delivered growth through launches of innovative therapies. At AMP, he builds a partner-centric commercial engine across BD&L, market access, and scaling operations.
Maxine Hamilton
Prior to joining AMP, Maxine was Idis’ SVP of Managed Access Programs in Princeton, NJ and the Managing Director of Managed Access following its acquisition by Clinigen.
Marco Wulff
Prior to joining AMP, Marco worked across the Abacus Medicine Group business heading up strategy and transformation projects.
Brett Wynn
Brett worked for the UK affiliate for Alliance Healthcare and Alcura, part of the former Walgreens Boots Alliance group, before joining AMP.
Alexander Iversen
Prior to joining AMP, Alexander was Head of Corporate Strategy at Abacus Medicine Group, with deep experience within product management.
Casper Johansen
Casper joined AMP in 2025. He brings over a decade of experience from Ferring Pharmaceuticals, where he held senior roles in business development with a focus on licensing and external innovation. Casper is responsible for driving business development and expanding the portfolio of specialty medicines through new partnerships.